Business Medical Dialogues
    • facebook
    • twitter
    Sign in Signup
    • facebook
    • twitter
    Sign in Signup
    • Medical Dialogues
    • Speciality Dialogues
    • Education Dialogues
    • Medical Jobs
    • Medical Matrimony
    • MD Brand Connect
    Business Medical Dialogues
    • News
        • Financial Results
        • Hospitals & Diagnostics
        • IT / Health Venture
        • Implants / Devices
        • Insurance
        • Key Movement
        • Pharmaceuticals
        • Policy
        • Technology
        • pharma-news
    • blog
    Sign InRegister
    Business Medical Dialogues
    Sign inRegister
    • Home
    • News
      • Financial Results
      • Hospitals & Diagnostics
      • IT / Health Venture
      • Implants / Devices
      • Insurance
      • Key Movement
      • Pharmaceuticals
      • Policy
      • Technology
      • pharma-news
    • blog
    • Home
    • Latest News
    • Dynavax hepatitis B...

    Dynavax hepatitis B vaccine gets FDA nod on third try, shares up

    By Ruby Khatun KhatunPublished On 2017-11-11T09:45:47+05:30  |  Updated On 2021-08-18T14:16:22+05:30

    Dynavax Technologies Corp's hepatitis B vaccine won the U.S. Food and Drug Administration's approval on the third attempt and Chief Executive Eddie Gray told Reuters the company was open to, but not waiting for, a partner to market the drug.


    The two-dose vaccine, Heplisav-B, will be Dynavax's first drug to come to market and its approval comes after two FDA rejections, first in February 2013 and then in November 2016.



    The company's shares jumped 16.5 percent to $23.35 in extended trading on Thursday.

    Reuters reported in September that Dynavax was exploring strategic options, including a sale or licensing deal, for Heplisav-B, which is designed to enhance the body's immune response to the hepatitis B virus in adults.


    Gray told Reuters he is willing to discuss any proposal for a potential partnership on the drug, but said Dynavax is not waiting for approaches and is moving ahead with a launch in the first quarter of 2018.


    "The adult vaccine market is an ideal market opportunity for Dynavax to become a commercial entity and to be highly successful with Heplisav-B," Gray said.


    The vaccine will compete directly with GlaxoSmithKline Plc's Engerix-B, a three-dose vaccine that currently dominates the market.


    William Blair analyst Katherine Xu believes Heplisav-B has the potential to become the next standard of care and could reach peak sales of about $600 million in the United States.


    "The two-dose vaccine ... is really a game changer," Xu said, adding that Heplisav-B could capture 80 percent of the market over the next couple of years.


    Hepatitis B affected about 3,370 patients in 2015, latest data from the Centers for Disease Control and Prevention showed.


    The virus can lead to cirrhosis of the liver, cancer and even death. It spreads through sexual contact, sharing needles or syringes and from mother to baby during pregnancy.


    A panel of independent advisers to the FDA in July had voted in favor of the safety of and recommended approving Heplisav-B.




    (Reporting by Divya Grover in Bengaluru; Editing by Savio D'Souza)



    aprroval Centers for Disease Control and Prevention cirrhosis Dynavax Eddie Gray Engerix-B FDA GlaxoSmithKline hepatitis B Heplisav-B pharma news U.S. Food and Drug Administration vaccine 
    Source : REUTERS

    Disclaimer: This site is primarily intended for healthcare professionals. Any content/information on this website does not replace the advice of medical and/or health professionals and should not be construed as medical/diagnostic advice/endorsement or prescription. Use of this site is subject to our terms of use, privacy policy, advertisement policy. © 2020 Minerva Medical Treatment Pvt Ltd

    Ruby Khatun Khatun
    Ruby Khatun Khatun
      Show Full Article
      Next Story
      Similar Posts
      NO DATA FOUND

      Popular Stories

      Johnson & Johnson Risperdal Lawsuit: US Court Slashes USD 8 Billion Verdict

      Johnson & Johnson Risperdal Lawsuit: US Court Slashes USD 8 Billion Verdict

      Covid-19 Impact: NPPA asks drugmakers to submit availablility data of 58 APIs, details

      Covid-19 Impact: NPPA asks drugmakers to submit availablility data of 58 APIs, details

      Delhi HC directs cashless service to all hospitals: GIPSA stayed on Ophthalmological Society petition

      Delhi HC directs cashless service to all hospitals: GIPSA stayed on Ophthalmological Society...

      Rising prices of hydroxychloroquine raw material forces small scale pharmas in Haridwar to stop production

      Rising prices of hydroxychloroquine raw material forces small scale pharmas in Haridwar to stop...

      Pharmaceuticals safe in PET packaging: High-level committee

      Pharmaceuticals safe in PET packaging: High-level committee

      Union Pharma Secretary Holds video conference with Pharma manufacturers and associations, takes feedback

      Union Pharma Secretary Holds video conference with Pharma manufacturers and associations, takes...

      NPPA fixes prices of 29 formulations under DPCO, check out details

      NPPA fixes prices of 29 formulations under DPCO, check out details

      Top priority on Delivery of Medicines through Speed Post: Minister

      Top priority on Delivery of Medicines through Speed Post: Minister

      View All

      • Email: info@medicaldialogues.in
      • Phone: 011 - 4372 0751

      Website Last Updated On : 29 March 2022 11:15 AM GMT
      Company
      • About Us
      • Contact Us
      • Our Team
      • Reach our Editor
      • Feedback
      • Submit Article
      Ads & Legal
      • Advertise
      • Advertise Policy
      • Terms and Conditions
      • Privacy Policy
      • Editorial Policy
      • Comments Policy
      • Disclamier

      This website is certified by Health On the Net Foundation. Click to verify. This site complies with the HONcode standard for trustworthy health information:
      verify here.

      Search only trustworthy HONcode health websites:

      Medical Dialogues is health news portal designed to update medical and healthcare professionals but does not limit/block other interested parties from accessing our general health content. The health content on Medical Dialogues and its subdomains is created and/or edited by our expert team, that includes doctors, healthcare researchers and scientific writers, who review all medical information to keep them in line with the latest evidence-based medical information and accepted health guidelines by established medical organisations of the world.

      Any content/information on this website does not replace the advice of medical and/or health professionals and should not be construed as medical/diagnostic advice/endorsement or prescription.Use of this site is subject to our terms of use, privacy policy, advertisement policy. You can check out disclaimers here. © 2020 Minerva Medical Treatment Pvt Ltd

      © 2020 - Medical Dialogues. All Rights Reserved.
      Powered By: Hocalwire
      We use cookies for analytics, advertising and to improve our site. You agree to our use of cookies by continuing to use our site. To know more, see our Cookie Policy and Cookie Settings.Ok
      X
      X